Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;177(1):63-67.
doi: 10.1007/s10517-024-06132-w. Epub 2024 Jul 2.

Antiplatelet and Antithrombotic Properties of Compound L-36, a 6H-1,3,4-Thiadiazine Derivative

V S Sirotenko  1 , A A Spasov  2 , A F Kucheryavenko  2 , K A Gaidukova  2 , A V Smirnov  3 , Yu I Velikorodnaya  3
Affiliations

Antiplatelet and Antithrombotic Properties of Compound L-36, a 6H-1,3,4-Thiadiazine Derivative

V S Sirotenko et al. Bull Exp Biol Med. 2024 May.

Abstract

Compound L-36, a new derivative of 6H-1,3,4-thiadiazine, was studied in in vitro and in vivo experiments. This compound exhibits high antiplatelet and antithrombogenic activity. In in vitro experiments, compound L-36 by its antiplatelet activity (by IC50) was superior to acetylsalicylic acid by 9.4 times. In in vivo experiments, compound L-36 by its ED50 value was close to the comparison drug. On the model of pulmonary artery thrombosis, compound L-36 ensured better survival of experimental animals than acetylsalicylic acid. Morphological studies showed that compound L-36 effectively attenuated the thrombosis processes in the pulmonary tissue induced by intravenous injection of a thrombogenic mixture (epinephrine and collagen).

Keywords: acetylsalicylic acid; antiplatelet activity; antithrombotic effect; arterial thrombosis; derivatives of 6H-1,3,4-thiadiazine.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Saito Y, Kobayashi Y. Update on antithrombotic therapy after percutaneous coronary intervention. Intern. Med. 2020;59(3):311-321. doi: https://doi.org/10.2169/internalmedicine.3685-19 - DOI - PubMed
    1. Thiele H, Jobs A. ESC guidelines 2020: acute coronary syndrome without persistent ST-segment elevation: What is new? Herz. 2021;46(1):3-13. doi: https://doi.org/10.1007/s00059-020-05002-1 - DOI - PubMed
    1. Mirzoian RS, Shabalina AA, Gan’shina TS, Kurdyumov IN, Turilova AI, Kostochka LM, Kozlov AV, Annushkin VA, Kornilova AA, Tanashyan MM. Expanding the horizons of antiplatelet therapy. A pilot study of the antiplatelet properties of a new tropane alkaloid. Ann. Klin. Eksper. Nevrol. 2020;14(3):53-59. Russian. https://doi.org/10.25692/ACEN.2020.3.7
    1. Pryakhin IS, Murashko SS, Berns SA, Pasechnik IN, Arsen’yeva NV, D’yakova MP, Gafurova NM, Goncharova MA, Gorshkolepova OL. Aggregation of thrombocytes as a marker of efficiency and safety of antiplatelet therapy in patient with ischemic heart disease. Kreml. Med. Klin. Vestn. 2020;(1):64-71. Russian. https://doi.org/10.26269/hb8d-qg49
    1. Sarapultsev A, Vassiliev P, Grinchii D, Kiss A, Mach M, Osacka J, Balloova A, Paliokha R, Kochetkov A, Sidorova L, Sarapultsev P, Chupakhin O, Rantsev M, Spasov A, Dremencov E. Combined in silico, ex vivo, and in vivo assessment of L-17, a thiadiazine derivative with putative neuro- and cardioprotective and antidepressant effects. Int. J. Mol. Sci. 2021;22(24):13626. doi: https://doi.org/10.3390/ijms222413626 - DOI - PubMed - PMC

LinkOut - more resources